Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Toxicity of internal mammary irradiation in breast cancer. Are concerns still justified in times of modern treatment techniques

KJ. Borm, C. Simonetto, P. Kundrát, M. Eidemüller, M. Oechsner, M. Düsberg, SE. Combs

. 2020 ; 59 (10) : 1201-1209. [pub] 20200703

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026493

BACKGROUND: The purpose of this study was to estimate the additional risk of side effects attributed to internal mammary node irradiation (IMNI) as part of regional lymph node irradiation (RNI) in breast cancer patients and to compare it with estimated overall survival (OS) benefit from IMNI. MATERIAL AND METHODS: Treatment plans (n = 80) with volumetric modulated arc therapy (VMAT) were calculated for 20 patients (4 plans per patient) with left-sided breast cancer from the prospective GATTUM trial in free breathing (FB) and in deep inspiration breath hold (DIBH). We assessed doses to organs at risk ((OARs) lung, contralateral breast and heart) during RNI with and without additional IMNI. Based on the OAR doses, the additional absolute risks of 10-year cardiac mortality, pneumonitis, and secondary lung and breast cancer were estimated using normal tissue complication probability (NTCP) and risk models assuming different age and risk levels. RESULTS: IMNI notably increased the mean OAR doses. The mean heart dose increased upon IMNI by 0.2-3.4 Gy (median: 1.9 Gy) in FB and 0.0-1.5 Gy (median 0.4 Gy) in DIBH. However, the estimated absolute additional 10-year cardiac mortality caused by IMNI was <0.5% for all patients studied except 70-year-old high risk patients (0.2-2.4% in FB and 0.0-1.1% in DIBH). In comparison to this, the published oncological benefit of IMNI ranges between 3.3% and 4.7%. The estimated additional 10-year risk of secondary cancer of the lung or contralateral breast ranged from 0-1.5% and 0-2.8%, respectively, depending on age and risk levels. IMNI increased the pneumonitis risk in all groups (0-2.2%). CONCLUSION: According to our analyses, the published oncological benefit of IMNI outweighs the estimated risk of cardiac mortality even in case of (e.g., cardiac) risk factors during VMAT. The estimated risk of secondary cancer or pneumonitis attributed to IMNI is low. DIBH reduces the estimated additional risk of IMNI even further and should be strongly considered especially in patients with a high baseline risk.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026493
003      
CZ-PrNML
005      
20211026132844.0
007      
ta
008      
211013s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/0284186X.2020.1787509 $2 doi
035    __
$a (PubMed)32619381
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Borm, Kai Joachim $u Department of Radiation Oncology, Technical University of Munich (TUM), München, Germany
245    10
$a Toxicity of internal mammary irradiation in breast cancer. Are concerns still justified in times of modern treatment techniques / $c KJ. Borm, C. Simonetto, P. Kundrát, M. Eidemüller, M. Oechsner, M. Düsberg, SE. Combs
520    9_
$a BACKGROUND: The purpose of this study was to estimate the additional risk of side effects attributed to internal mammary node irradiation (IMNI) as part of regional lymph node irradiation (RNI) in breast cancer patients and to compare it with estimated overall survival (OS) benefit from IMNI. MATERIAL AND METHODS: Treatment plans (n = 80) with volumetric modulated arc therapy (VMAT) were calculated for 20 patients (4 plans per patient) with left-sided breast cancer from the prospective GATTUM trial in free breathing (FB) and in deep inspiration breath hold (DIBH). We assessed doses to organs at risk ((OARs) lung, contralateral breast and heart) during RNI with and without additional IMNI. Based on the OAR doses, the additional absolute risks of 10-year cardiac mortality, pneumonitis, and secondary lung and breast cancer were estimated using normal tissue complication probability (NTCP) and risk models assuming different age and risk levels. RESULTS: IMNI notably increased the mean OAR doses. The mean heart dose increased upon IMNI by 0.2-3.4 Gy (median: 1.9 Gy) in FB and 0.0-1.5 Gy (median 0.4 Gy) in DIBH. However, the estimated absolute additional 10-year cardiac mortality caused by IMNI was <0.5% for all patients studied except 70-year-old high risk patients (0.2-2.4% in FB and 0.0-1.1% in DIBH). In comparison to this, the published oncological benefit of IMNI ranges between 3.3% and 4.7%. The estimated additional 10-year risk of secondary cancer of the lung or contralateral breast ranged from 0-1.5% and 0-2.8%, respectively, depending on age and risk levels. IMNI increased the pneumonitis risk in all groups (0-2.2%). CONCLUSION: According to our analyses, the published oncological benefit of IMNI outweighs the estimated risk of cardiac mortality even in case of (e.g., cardiac) risk factors during VMAT. The estimated risk of secondary cancer or pneumonitis attributed to IMNI is low. DIBH reduces the estimated additional risk of IMNI even further and should be strongly considered especially in patients with a high baseline risk.
650    _2
$a senioři $7 D000368
650    _2
$a nádory prsu $x radioterapie $7 D001943
650    _2
$a zadržování dechu $7 D062485
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdce $x účinky záření $7 D006321
650    _2
$a nemoci srdce $x mortalita $7 D006331
650    _2
$a lidé $7 D006801
650    _2
$a kritické orgány $7 D058958
650    _2
$a prospektivní studie $7 D011446
650    _2
$a radiační poranění $x mortalita $7 D011832
650    _2
$a radioterapie $x škodlivé účinky $x mortalita $7 D011878
650    12
$a celková dávka radioterapie $7 D011879
650    _2
$a plánování radioterapie pomocí počítače $7 D011880
655    _2
$a časopisecké články $7 D016428
700    1_
$a Simonetto, Cristoforo $u Institute of Radiation Medicine, Helmholtz Zentrum München, Neuherberg, Germany
700    1_
$a Kundrát, Pavel $u Institute of Radiation Medicine, Helmholtz Zentrum München, Neuherberg, Germany $u Department of Radiation Dosimetry, Nuclear Physics Institute of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Eidemüller, Markus $u Institute of Radiation Medicine, Helmholtz Zentrum München, Neuherberg, Germany
700    1_
$a Oechsner, Markus $u Department of Radiation Oncology, Technical University of Munich (TUM), München, Germany
700    1_
$a Düsberg, Mathias $u Department of Radiation Oncology, Technical University of Munich (TUM), München, Germany
700    1_
$a Combs, Stephanie Elisabeth $u Department of Radiation Oncology, Technical University of Munich (TUM), München, Germany $u Institute of Radiation Medicine, Helmholtz Zentrum München, Neuherberg, Germany $u Deutsches Konsortium für Translationale Krebsforschung, (DKTK)-Partner Site Munich, München, Germany
773    0_
$w MED00009028 $t Acta oncologica (Stockholm, Sweden) $x 1651-226X $g Roč. 59, č. 10 (2020), s. 1201-1209
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32619381 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132851 $b ABA008
999    __
$a ok $b bmc $g 1715268 $s 1147000
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 59 $c 10 $d 1201-1209 $e 20200703 $i 1651-226X $m Acta oncologica $n Acta Oncol $x MED00009028
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace